AGN
$13M8mo
Argenica Therapeutics Limited
Neurology
Developing neuroprotective peptide ARG-007 for stroke, traumatic brain injury, and hypoxic ischaemic encephalopathy
Cash data from Mar 2026 4CFigures from ASX filings · not financial advice
[ VITALS ]
Cash on Hand
$8.0M
Mar 2026 4C
Runway
8moCAUTION
Based on Mar 2026 4C
Market Cap
$13M
Burn Rate
$2.9M/qtr
Mar 2026 4C
Shares Outstanding
128M
Pipeline Assets
3
Latest Insightprice-sensitive announcements & broker notes
Price-sensitiveRegulatory10 June 2026
ARG007 (Xaranetide) Completes All Three FDA Requested Assays
Argenica Therapeutics completed all three FDA-requested safety assays (hERG, TNK, and genotox) required to lift an IND clinical hold on ARG-007 (xaranetide), with all three demonstrating clean and favourable safety profiles. The company intends to submit a comprehensive response to the FDA clinical hold to seek reinstatement of the IND and enable Phase 2b clinical trials in the United States.
FDA·Acute ischaemic stroke·positive
3M Price
AGN.ASX$0.110-50.0% 3M
Low $0.110High $0.220
Pipeline Assets (3)
Capital Raises & Buybacks
show_chart
No capital raise or buyback data
Other ticker dataInsider activity, holders, grants, publications
expand ›
Insider activity, holders, grants, publications
Director Options & Rights
Director
Outstanding
Ex. Price
Expiry
No option data entered yet
R&D Tax Incentive
$4.0M received43.5% ATO refund
FY2026received
Auto-extracted from 4C (2026-03-31)
$3.98M
How the R&D Tax Incentive works
Australian biotechs with < $20M aggregated turnover can claim a 43.5% refundable tax offseton eligible R&D expenditure each financial year (Jul–Jun). This is paid as a cash refund by the ATO — not a tax deduction — making it non-dilutive capital that directly extends cash runway.
Companies register eligible R&D activities with AusIndustry during the year, then lodge their tax return after 30 June. Refunds typically arrive October–Decemberof the same calendar year. For a company spending $5M/year on R&D, this is a ~$2.2M annual cash inflow.
Disclaimer: Amounts shown as or are forward-looking estimates based on disclosed R&D expenditure and the 43.5% offset rate. Actual refunds may differ due to ATO assessments, eligibility rulings, or changes in R&D spend. This is not financial advice. Manually curated from 4C filings and company disclosures — verify independently.
Catalysts (7)· 1 upcoming · 6 past
ExpectedremoveMed30 June 2026
Related activity
9 June 2026 · WHO Confirms Xaranetide as INN for ARG-007expand_more6 past catalysts
Track RecordDelivery Consistency Index
expand ›
Delivery Consistency Index
Historical delivery and spending consistency. Data is limited for recently added companies.
Delivery Consistency Index
Delivery
–Insufficient data
2/3 data points needed
Timeline adherence · phase-adjusted tolerance · recency-weighted · min 3 catalysts
Capital discipline
High98/100(limited data)
Burn rate stability · stage-adjusted thresholds · runway trend · R&D focus
Hit 2 of 2 guided dates· rolling 2yr(limited sample)· of 7 tracked
Filed 1 of 1 4Cs on time· statutory deadline· 1 filing without matched announcement
What drove these scores · rolling 2yr
arrow_drop_up
Stable burn rate — 3% quarterly variation — consistent spend
arrow_drop_up
R&D-focused spend — 93% of opex directed to R&D
Completed catalysts
✓WHO Confirms Xaranetide as INN for ARG-007— WHO has confirmed xaranetide as the International Nonproprietary Name (INN) for Argenica's lead drug candidate ARG-007 with no objections during public consultation. The recommended INN status is expected to be published shortly, establishing a globally recognised generic name for the neuroprotective therapeutic in development for stroke and acute neurological conditions.
On time
✓ARG-007 (Xaranetide) FDA — ARG007 (Xaranetide) Completes All Three FDA Requested Assays— Argenica Therapeutics completed all three FDA-requested safety assays (hERG, TNK, and genotox) required to lift an IND clinical hold on ARG-007 (xaranetide), with all three demonstrating clean and favourable safety profiles. The company intends to submit a comprehensive response to the FDA clinical hold to seek reinstatement of the IND and enable Phase 2b clinical trials in the United States.
On time
Outcome quality (positive/negative readouts) reflects the science, not execution — shown above but excluded from the score.
These metrics reflect historical operational data only. They are not predictive of future performance, do not constitute investment advice, and should not be used as the basis for any investment decision.
Clinical Trials(1)
No active trials
Announcements(15)
verified
RegulatoryPSauto_awesome
ARG007 (Xaranetide) Completes All Three FDA Requested Assays10 June 2026
expand_more322KB